iOmx Therapeutics focuses on the development of cancer immunotherapy treatments.
IOmx Therapeutics has raised $75.4M in total funding. The most recent round was Series B. The last funding was announced in October 2021.
IOmx Therapeutics's investors include Sofinnova Partners, Wellington Partners, MPM Capital, M Ventures, MIG Capital.
IOmx Therapeutics is headquartered in Munich, Germany.
iOmx Therapeutics focuses on the development of cancer immunotherapy treatments.
IOmx Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"IOmx Therapeutics — Funding & Investors." VCBacked, October 5, 2021, https://www.vcbacked.co/company/iomx-therapeutics. Accessed August 15, 2026.
VCBacked. (2021). IOmx Therapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/iomx-therapeutics
{{cite web |title=IOmx Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/iomx-therapeutics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated